|
Reference
|
|
Ambrosius, W., Michalak, S., Kozubski, W., Kalinowska, A. (2020) Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease: Current Insights into the Disease Pathophysiology, Diagnosis and Management. Int J Mol Sci, 22(1): 100-100
|
|
Baumann, M., Grams, A., Djurdjevic, T., Wendel, E.A., Lechner, C., Behring, B., et al. (2018) MRI of the First Event in Pediatric Acquired Demyelinating Syndromes with Antibodies to Myelin Oligodendrocyte Glycoprotein. J Neurol, 265(4): 845-855
|
|
Baumann, M., Sahin, K., Lechner, C., Hennes, E.M., Schlanda, K., Mader, S., et al. (2015) Clinical and Neuroradiological Differences of Paediatric Acute Disseminating Encephalomyelitis with and Without Antibodies to the Myelin Oligodendrocyte Glycoprotein. J Neurol Neurosur Psychiatry, 86(3): 265-272
|
|
Bruijstens, A.L., Wendel, E.A., Lechner, C., Bartels, F., Finke, C., Breu, M., et al. (2020) E.U. Paediatric MOG Consortium Consensus: Part 5: Treatment of Paediatric Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disorders. Eur J of Paediatr Neurol, 29: 41-53
|
|
Hacohen, Y., Wong, Y.Y., Lechner, C., Jurynczyk, M., Wright, S., Konuskan, B., et al. (2018) Disease Course and Treatment Responses in Children With Relapsing Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease. JAMA Neurol, 75(4): 478-478
|
|
Jarius, S., Ruprecht, K., Kleiter, I., Borisow, N., Asgari, N., Pitarokoili, K., et al. (2016) MOG-IgG in NMO and Related Disorders: a Multicenter Study of 50 Patients: Part 1: Frequency, Syndrome Specificity, Influence of Disease Activity, Long-term Course, Association with AQP4-IgG, and Origin. J Neuroinflammation, 13(1): 279-279
|
|
Klein, da C.B., Banwell, B.L., Kazutoshi, S.D. (2021) Treatment of MOG-IgG Associated Disease in Paediatric Patients: A Systematic Review. Mult Scler Relat Disord, 56: 103216
|
|
Krupp, I.B., Tardieu, M., Amato, M.P., Banwell, B., Chitnis, T., Dale, R.C., et al. (2013) International Pediatric Multiple Sclerosis Study Group Criteria for Pediatric Multiple Sclerosis and Immune-Mediated Central Nervous System Demyelinating Disorders: Revisions to the 2007 Definitions. Mult Scler, 19(10): 1261-1267
|
|
Lana-Peixoto, M.A., Talim, N. (2019) Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes. Biomedicines, 7(2): 42-42
|
|
Ogawa, R., Nakashima, I., Takahashi, T., Kaneko, K., Akaishi, T., Takai, Y., et al. (2017) MOG Antibody-Positive, Benign, Unilateral, Cerebral Cortical Encephalitis with Epilepsy. Neurol Neuroimmunol Neuroinflamm, 4(2): e322
|
|
Panzer, J., Dalmau, J. (2011) Movement Disorders in Paraneoplastic and Autoimmune Disease. Curr Opin Neurol, 24(4): 346-353
|
|
Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T.K., Merheb, V., Fung, V.S.C., et al. (2018) Clinical Course, Therapeutic Responses and Outcomes in Relapsing MOG Antibody-Associated Demyelination. J Neurol Neurosurg Psychiatry, 89(2): 127-137
|
|
Reindl, M., Jarius, S., Rostasy, K., Berger, T. (2017) Myelin Oligodendrocyte Glycoprotein Antibodies: How Clinically Useful Are They?. Curr Opin Neurol, 30(3): 295-301
|
|
Sa, M., Thornton, R., Chong, W.K., Kaliakatsos, M., Hacohen, Y. (2019) Paediatric MOG Antibody-Associated ADEM with Complex Movement Disorder: A Case Report. Mult Scler J, 25(1): 125-128
|
|
Tenembaum, S.N. (2021) Pediatric Demyelinating Disease and Anti-MOG Antibody. Clin Exp Neuroimmunol, 12: 7-21
|
|
Wang, X., Zhao, R., Yang, H., Liu, C., Wang, W., Liu, T., et al. (2022) Clinical Analysis of Myelin Oligodendrocyte Glycoprotein Antibody-Associated Demyelination in Children: A Single-Center Cohort Study in China. Mult Scler Relat Disord, 58: 103526
|
|
Wegener-Panzer, A., Cleavelend, R., Wendel, E.M., Baumann, M., Bertolini, A., Hausler, M., et al. (2020) Clinical and Imaging Features of Children with Autoimmune Encephalitis and MOG Antibodies. Neurol Neuroimmunol Neuroinflamm, 7(4): e731
|
|
Wynford-Thomas, R., Jacob, A., Tomassini, V. (2019) Neurological Update: MOG Antibody Disease. J Neurol, 266(5): 1280-1286
|
|
|
|